KIT and ischemic cardiomyopathy: The results of the SCIPIO trial indicate that that intracoronary delivery of autologous c-kit+ CSCs is not only safe, but also leads to a significant and clinical improvement in patients with ischemic cardiomyopathy, which is supported by the substantial and continuous improvement in LV systolic function and reduction in infarct size in the treated group.